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As in other leukemia, abnormal expression of several miRNAs is reported in chronic myeloid leukaemia (CML).
2 Downregulation of miR10a leads to abnormal proliferation of CML cells through regulation of USF2 gene expression, whereas forced expression of miR-328 that is lost in the blast phase of the disease rescues C/EBP alpha-driven granulocytic maturation and impairs survival of CML cells. 3, 4 Recently, one of the miRNA that is attracting considerable attention in hematopoiesis is miR-223 as it resembles a myeloid gene and its expression is known to increase towards myeloid differentiation. Expression of miR-223, which was identified bioinformatically, is controlled by three transcription factors, C/EBPa, PU.1 and NFI-A. C/ EBP-a and PU.1 positively regulates miR-223, whereas NFI-A competes for C/EBPa binding site and maintains miR-223 at low levels. 5, 6 BCR-ABL inhibits the translation of C/EBPa mRNA by stabilizing the RNA-binding protein hnRNP E2. 7 As CML is characterized by chronic granulocytic maturation arrest and the transcription factors involved in miR-223 expression are deregulated in CML, we predicted that miR-223 may have a role in CML disease biology.
We investigated the miR-223 and BCR-ABL expression pattern in the peripheral blood samples from CML patients (n ¼ 35) by real-time quantitative PCR (RQ-PCR). Relative expression values for each sample were calculated by using 2 À DCt method. Spearman's correlation test shows the existence of a negative correlation between the expression profiles of BCR-ABL and miR-223 ( Figure 1a ). To further validate this, bone marrow mononuclear cells from three untreated CML patients were isolated and treated with 2 mM imatinib, a BCR-ABL kinase inhibitor. After 48 h of treatment, miR-223 expression was analyzed by RQ-PCR. MiR-223 expression was upregulated in imatinib-treated bone marrow mononuclear cells as compared with dimethyl sulfoxide control (Figure 1b) . Hence, these studies support the notion that BCR-ABL mediates repression of miR-223, probably, by deregulating C/EBPa. However, normal and complete hematological response (CHR) cases failed to show any appreciable correlation with naive CML cases as because of the different cell type.
MiR-223 relative expression was correlated in CML with the available clinical parameters. Among the available clinical data, sokal score and neutrophil percentage were found to be significant. MiR-223 expression was positively correlated with mature neutrophil percentage, and this data also supports the role of miR-223 in granulocytic maturation as shown by Fazi et al. 6 (data not shown). Spearman's correlation test demonstrated the existence of a negative correlation between miR-223 expression levels and sokal score. This suggests that miR-223 expression is negatively correlated with disease risk (Figure 1c ) and may be used as a disease-risk prediction marker.
To define the role of miR-223 in CML, we generated a cell line model system in which K562 cells were transduced with a lentiviral vector expressing miR-223. After 7 days of transduction, K562 cells were analyzed for miR-223 expression to confirm the overexpression of miR-223 ( Figure 1d ). To verify the role of miR-223 in granulocytic maturation, we analyzed myeloperoxidase expression at the RNA level. Figure 1e shows that MPO is upregulated at mRNA level in miRNAs are small noncoding RNA molecules that negatively regulate gene expression via degradation or translational repression of their target mRNA. During granulopoiesis, C/EBPa binds and transactivates miR-223 promoter, which is turn deregulates E2F1 that eventually inhibits cell-cycle progression, resulting in myeloid differentiation. 8 The above process is reversed when C/EBPa is deregulated by several oncogenes, which induces myeloid cell-cycle progression and a block in differentiation as seen in acute myeloid leukemia. 9 To identify the downstream targets of miR-223 in CML, we adopted the following strategy. We downloaded the miR-223 knockout mice gene-expression microarray data from gene expression omnibus (GEO) (GSE12075 and GSE22003). 10, 11 Significantly, upregulated genes were taken into consideration. As imatinib treatment upregulates miR-223, enriched genes were further hybridized with another geneexpression microarray data (GSE1922) in which K562 cells were treated with 1 mM imatinib. Genes that were upregulated in miR-223 knockout array data and downregulated by imatinib in K562 were further hybridized with miR-223 targets predicted by TargetScan 5.1 (http://www.targetscan.org). This workflow will give the miR-223 targets that were upregulated in CML (Figure 2a ). All microarray data were analyzed by using Genespring Gx 11.0 (Agilent technologies Inc, Santa Clara, CA, USA).
Enriched genes were further validated by RQ-PCR in miR-223 transduced K562 cells. Three genes PURB, MEF2C and PTBP2 were found to be downregulated in miR-223 transduced K562 cells (Figure 2b) . We have analyzed the expression profiles of the above targets in patient samples. PTBP2 and MEF2C expression was significantly upregulated in CML samples, and shows a negative correlation with miR-223 (Figures 2c and d) . MEF2C is already a validated miR-223 target; however, this has not yet been reported in CML. MEF2C and PTBP2 upregulation was further confirmed by Oncomine database (CML data set-Radich leukemia set). As it is known that miR-223 is downregulated in disease progression, Radich data set shows that both MEF2C and PTBP2 are upregulated with disease progression (CML chronic phase (CP) to accelerated phase (AP) to blast crisis (BC)). Transcription factor MEF2C, required for cell survival and proliferation, is important for lymphopoiesis, and its ectopic expression in myeloid progenitors antagonizes myelopoiesis. 12 Hence, MEF2C may contribute to delayed maturation of myeloid progenitors in CML. MEF2C expression was downregulated in K562 cells using two specific siRNA. Although there was no change in myeloperoxidase, we found that there is a significant reduction in cell proliferation with a significant downregulation of the survival gene Bcl-xL (Supplementary Figure 1) . This data show that MEF2C can affect myeloid cell proliferation instead of differentiation in K562 cells. PTBP2 is a RNA-binding neuronal-specific protein that splices nuclear transcripts and stabilizes specific miRNAs in the cytoplasm. PTBP2 and its homologue PTBP1 are involved in regulated exon inclusion in addition to its widely perceived role in exon skipping. 13 We did not evaluate the protein expression of PTBP2 and MEF2C because of lack of cells. Thus, downregulation of miR-223 and upregulation of PTBP2 in CML CP cases can contribute to abnormal splicing and stabilization of certain factors, which can eventually help in disease progression.
To further investigate the mechanism of PTBP2 repression by miR-223, we targeted the PTBP2 (m) 3 0 UTR downstream of a luciferase reporter gene with miR-223 (Figure 2e) . In 293T cells, miR-223 was able to reduce luciferase activity by 68%, indicating that this miRNA may directly target the PTBP2 3 0 UTR (Figure 2f , first and second bar). This reduction was abolished by a 3 0 UTR that contains specific mutations in the seed region (from 5 0 -UUUCUAAAACUGA-CAA-3 0 to 5 0 -UUUCUAAAACACUCAA-3 0 ) of the miR-223 target sequence, indicating that miR-223 can directly influence PTBP2 protein level through specific binding to its 3 0 UTR (Figure 2f , third and fourth bar). The above data support that PTBP2 is a direct target of miR-223 and it acts through the 8 0 mer conserved binding site, which is present in the PTBP2 3 0 UTR. This target site is well conserved in other vertebrates, suggesting that miR-223 may control PTBP2 levels in wide range of organisms and diseases.
A connection between miRNAs and hematopoiesis was made when it was demonstrated that certain miRNAs are expressed within specific hematopoietic lineages, and their expression levels regulate hematopoietic differentiation.
14 In this study, we report that miR-223 downregulation affects the transcription factor MEF2C and alternative splicing factor PTBP2. It has been long recognized that alternative splicing can generate numerous protein isoforms, at times with variant function, which are encoded by the same pre-RNA transcript. BCR-ABL dependent increase in expression of multiple genes involved in pre-mRNA splicing is already reported (for example, SRPK1, RNA helicase II/Gsi and hnRNP A2/B1). 15 Taken together, these results suggest that changes in the miR-223/PTBP2 pathway could contribute to the abnormal splicing of several genes and shed light into the potential role exerted by miRNAs in a subset of CML. Not only did it highlight the ability of miRNAs to alter mRNA but also, more importantly, it added a new layer to the complexity of mechanisms regulating the phenotype of CML.
